Similar articles

• American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.

  Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. Lichtenstein GR, et al. Gastroenterology. 2006 Mar;130(3):935-9. doi: 10.1053/j.gastro.2006.01.047. Gastroenterology. 2006. PMID: 16530531 No abstract available.
• American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.

  Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. Lichtenstein GR, et al. Gastroenterology. 2006 Mar;130(3):940-87. doi: 10.1053/j.gastro.2006.01.048. Gastroenterology. 2006. PMID: 16530532 Review. No abstract available.
• [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].

  Tanczos BT, Baumgart DC. Tanczos BT, et al. Z Gastroenterol. 2006 Jul;44(7):609-10. doi: 10.1055/s-2006-926668. Z Gastroenterol. 2006. PMID: 16823703 German. No abstract available.
• [Current status of new drug development for inflammatory bowel diseases].

  Kohgo Y, Tanabe H, Fujiya M. Kohgo Y, et al. Nihon Rinsho. 2012 Feb;70 Suppl 1:378-82. Nihon Rinsho. 2012. PMID: 23126121 Japanese. No abstract available.
• Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.

  Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS. Whitlock SM, et al. J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043. J Am Acad Dermatol. 2018. PMID: 29332708 Review.